(More on Moderna here: https://www.keionline.org/moderna) Luis Gil Abinader has taken a deep dive into Moderna’s surprising practice of never declaring government funding in its 126 patents and 154 patent applications, despite having had funding from multiple federal agencies. One outcome… Continue Reading
(Update: The NIH provided a response to our comments on August 24, 2020) On August 20, 2020, Knowledge Ecology International (KEI) submitted comments regarding the prospective grant of an exclusive license by the National Institutes of Health (NIH) to PreciThera,… Continue Reading
On August 14, 2020, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the NIH’s “Prospective Grant of an Exclusive Patent License: Allogeneic Therapy Using Chimeric Antigen Receptors Targeting GPC3” (85 FR 45912). The… Continue Reading
On Friday, 24 July 2020, Italy officially published the long-anticipated Pricing and Reimbursement Decree in the Gazzetta Ufficiale della Repubblica Italiana setting in motion Italy’s place as the first country to implement the WHO transparency resolution (WHA72.8). In statement before… Continue Reading
On 30 July 2020, the World Trade Organization (WTO) convened a formal meeting of the TRIPS Council. The TRIPS Council held discussions on two COVID-19 related topics: agenda item 3 on IP Measures in the Context of COVID-19 and agenda… Continue Reading
(More on Moderna here: https://www.keionline.org/moderna) On August 5, 2020, BARDA Acting Director Gary Disbrow sent KEI and Public Citizen a letter (PDF copy) responding to KEI and Public Citizen’s joint letter outlining how Moderna failed to honor a term of… Continue Reading
(More on Moderna here: https://www.keionline.org/moderna) On July 31, 2020, Knowledge Ecology International and Public Citizen sent Biomedical Advanced Research and Development Authority (BARDA) a letter asking BARDA to enforce a term of Moderna’s billion dollar contract with BARDA to develop… Continue Reading
Below is a letter from several individuals and groups, asking that NIAID not grant exclusive rights in a HIV patent license for South Africa, India and other low income countries. (PDF version here) The license is to RNAceuticals, a firm… Continue Reading